“For ITV-1, we know Danhson was supposed to be making ITV-1 for trials by Clinic Design to get EMA approval, then Scendea was to assist in obtaining FDA approval once EMA approval was granted. (source)”
And here is a great example of the ongoing problem. That press release is well over a year old and we still are in the dark as to where that information currently stands now.
There’s just too much speculation and confusion here bc we are basically in the dark for over a year on many things. What you linked above is a great example and Samsung Bio is just one other. A year and a half now since the Samsung Bio PR, and we have been given no real answers since. Grueling two year wait for the completed audit after shareholders were initially told different, and now he’s sat on the audit for an entire quarter in silence since it finally was completed.
It’s kind of pointless for me to go on and on. Nothing is going to change on our end as shareholders until Charles goes SEC reporting.
If these guys wanted to remain in the shadows and keep their dealings so secretive, then they should have remained private. They are a publicly traded company and we’ve questioned many times here the line between progressing in silence and the fiduciary duty to shareholders. Majority of press releases for the past two years have been rehashed promises and lacked any real substance to them.
Anyway, this is just becoming another rant of my frustration boiling over yet again so I’ll end it here.
Let’s just hope to put this all behind soon and that he finally goes SEC reporting by the required yearly update next month.
News 
Market Data 
Discover 
AI
